ELMMB logo
Facebook logo Twitter logo
MHRA Drug Safety Updates
MHRA Drug Safety Updates


MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Items In This Category

application/pdfDrug Safety Update MHRA October pdf.pdf (246KB)27/10/2017Download
 Methylprednisolone inj medicines containing lactose Gabapentin: risk of severe respiratory depression Clozapine: reminder of potentially fatal risk of intestinal obstruction, 
application/pdfDrug safety Update MHRA Sept-pdf.pdf (230KB)27/10/2017Download
 Miconazole (Daktarin) OTC oral gel contra-indications in patients taking warfarin. Loperamide: reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or... 
application/pdfDrug Safety Update MHRA August PDF.pdf (260KB)27/10/2017Download
 Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections Corticosteroids: risk of central serous chorioretinopathy with... 
application/pdfDrug Safety Update MHRA July 2017 PDF.pdf (229KB)26/07/2017Download
 Daclizumab (Zinbryta▼) and risk of severe liver injury, Bendamustine (Levact, Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection 
application/pdfDrug safety Update June 2017 PDF.pdf (147KB)22/06/2017Download
 Denosumab reports of osteonecrosis of the external auditory canal, brimoniudine gel: risk of cardiovascular effects: not to be applied to damaged skin 
application/pdfDrug Safety Update May 2017 .pdf (200KB)26/05/2017Download
 Finasteride: rare reports of depression and suicidal thoughts 
application/pdfDrug Safety Update April 2017.pdf (132KB)28/04/2017Download
 Valproate and developmental disorders: new alert asking for patient review and further consideration of risk minimisation measures 
application/pdfDrug Safety Update March 2017.pdf (104KB)31/03/2017Download
application/pdfDrug Safety Update February 2017 (86KB)21/02/2017Download
application/pdfDrug Safety Update January 2017.pdf (252KB)20/01/2017Download
application/pdfDrug_Safety_Update October 2016.pdf (77KB)19/12/2016Download
 Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis. Letters sent to healthcare professionals in September 2016, including retigabine withdrawal 
application/pdfDrug Safety Update December 2016.pdf (217KB)19/12/2016Download
 Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects. Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially... 
Page: [1] [2] [3] [4] [5] [6] [7] [8]